The UK experienced a significant disruption to ADHD stimulant supply across 2023 and into 2024. This article explains what happened, what the supply position looks like now in mid-2026, and what to do if your prescription is delayed. As of the date this article was reviewed, the major disruption has largely resolved but pockets of intermittent supply issues continue for specific brands and formulations.
What happened in 2023 and 2024
In autumn 2023, the UK Department of Health and Social Care (DHSC) issued formal Medicine Supply Notifications about disruption to several ADHD stimulant medications [1, 2]. The disruption affected:
- Several modified-release methylphenidate brands, including Concerta XL, Equasym XL and Medikinet XL
- Lisdexamfetamine (Elvanse and Elvanse Adult)
- Some immediate-release methylphenidate preparations
The causes were multifactorial and reflected a combination of:
- A sharp rise in UK ADHD prescriptions over the preceding years, outpacing manufacturer forecasting
- Manufacturing capacity constraints at the international level
- Specific manufacturing or supply chain issues for particular brands and formulations
- Strain on the controlled-drug supply chain, which has tighter regulatory requirements than non-controlled drug supply
The disruption was felt unevenly. Some patients changed pharmacies repeatedly. Some had to switch between brands of the same medication. Some patients faced unplanned gaps in supply, with the inevitable knock-on for symptoms, mental health and daily function. The disruption was particularly difficult for patients on long-acting modified-release stimulants where formulation differences matter clinically; not every modified-release methylphenidate brand has an equivalent release profile, and substitution is not always straightforward [3].
Where the supply position stands now
As of mid-2026, the major shortage has largely resolved. The DHSC has stepped down most of the formal supply notifications, manufacturers have increased capacity, and most patients are receiving their usual brand and formulation through their usual pharmacy without ongoing disruption.
Pockets of intermittent supply issues persist, however, particularly for specific modified-release brands and at specific times of year. The detailed picture changes month to month and is not stable enough to summarise in a fixed article. Patients can check the current position via the DHSC Medicine Supply Notifications, via their pharmacy, or by asking their prescriber.
Anyone reading this article more than a few months after the last reviewed date should check the current DHSC bulletins before relying on the supply picture described here. The shortage was dated content when it happened, and the resolution will be too.
What to do if a prescription is delayed
A few practical steps help when supply disruption affects you [3, 4]:
Speak to the pharmacy first
The pharmacy can usually tell you whether the issue is local or wider, whether they expect supply to recover within days or weeks, and whether another local pharmacy currently has stock. Many pharmacists are familiar with the recent shortage history and can advise practically.
Contact your prescriber
If a brand or formulation is genuinely unavailable for an extended period, your prescriber may consider:
- A switch to an equivalent brand of the same medication, where one exists
- A switch to a different medication, where appropriate
- A temporary change in formulation (for example from a long-acting modified-release stimulant to a combination of an immediate-release stimulant taken multiple times in the day)
None of these is a self-managed decision. All require prescriber input. For ADHD medication and prescribing with NeuroFX patients, this is part of the ongoing review pathway.
Do not split or stretch existing supply
Tempting as it can be to halve doses to make supply last longer, this is a prescriber decision rather than a patient decision. Schedule 2 controlled drug regulations also limit the safe and legal ways supply can be adjusted.
Plan ahead for repeat prescriptions
The 28-day quantity limit on Schedule 2 controlled drug prescriptions means there is less slack in the supply chain than for non-controlled drugs. Ordering a repeat one week before running out, rather than the day of running out, builds in time to absorb a pharmacy-level disruption.
Know what your alternatives are
Patients on Elvanse who have previously responded to methylphenidate (or vice versa) have a fallback option that prescribers can use during supply disruption. Patients who have only tried one stimulant family are more exposed to a brand-specific disruption.
What this means for the wider system
The 2023 to 2024 shortage exposed a structural issue: UK ADHD prescribing has grown faster than manufacturer planning anticipated, particularly for adult ADHD. The supply chain has since adjusted, but the system is not yet fully resilient to sudden demand changes.
DHSC, NHSE and pharmacy networks have made changes to forecasting, communication and emergency supply arrangements. The recognition that controlled drug supply requires more lead time than non-controlled drug supply has shaped how shortages are now flagged and managed. Patients and prescribers are likely to see fewer of the unannounced disruptions that characterised 2023.
What this article is not
This article is not a live supply tracker. The position changes regularly. The DHSC Medicine Supply Notifications and the BNF entries are the current authorities; this article describes the broader history and what to do, not the day-to-day stock picture.
What this means in practice
- A significant UK ADHD stimulant shortage ran across 2023 and into 2024 and has largely resolved as of mid-2026.
- Pockets of intermittent supply issues persist for specific brands; check the current DHSC bulletins for the live picture.
- If your prescription is delayed: speak to the pharmacy first, contact your prescriber if disruption is sustained, and do not adjust your own dose.
- Plan repeat prescriptions a week before running out to absorb pharmacy-level disruption.
- The system has adjusted but the underlying mismatch between rising demand and supply lead time is part of the long-term picture.
When to speak to a professional
Speak to your pharmacy first about any immediate supply question. Speak to your GP, your prescriber or NHS 111 if disruption is sustained, if you are running out, or if you are noticing significant return of ADHD symptoms because of a forced gap. Seek urgent help via 999 or A&E for any acute mental health crisis associated with sudden medication loss. NeuroFX provides private adult ADHD assessment and paediatric ADHD assessment for children aged 6 and upwards, with structured prescribing review across changes in supply or formulation.
Sources
- Department of Health and Social Care. Medicine Supply Notifications: methylphenidate prolonged-release preparations. https://www.gov.uk/drug-device-alerts
- Department of Health and Social Care. Medicine Supply Notifications: lisdexamfetamine. https://www.gov.uk/drug-device-alerts
- British National Formulary. Methylphenidate hydrochloride. https://bnf.nice.org.uk/drugs/methylphenidate-hydrochloride/
- British National Formulary. Lisdexamfetamine mesilate. https://bnf.nice.org.uk/drugs/lisdexamfetamine-mesilate/
- NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
